Literature DB >> 25631394

Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria.

E T Oliver1, P M Sterba, S S Saini.   

Abstract

Chronic spontaneous urticaria (CSU) significantly impacts the quality of life of those affected through symptoms of pruritus and recurrent skin lesions. In active CSU disease, reduced IgE-mediated basophil histamine release (HR) and basopenia are observed. We sought to examine the relationship between interval changes in basophil measures and shifts in patient-reported disease impairment. Simultaneous symptom and basophil evaluations were completed at two sequential study visits, and interval changes in measures were compared between visits for each subject (n = 38). These measures included Skindex-29, current itch and hives scores, total leukocyte histamine content (an indirect measure of blood basophil presence), and basophil HR in response to anti-IgE and formyl-methionine-leucine-phenylalanine. Overall, interval improvements in disease measures in CSU subjects were associated with increased basophil numbers (total leukocyte histamine content) and IgE-mediated HR. This suggests these measures are potential biomarkers for CSU disease improvement and further implicates a role for basophils in CSU.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  basophil; urticaria

Mesh:

Year:  2015        PMID: 25631394     DOI: 10.1111/all.12578

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  15 in total

1.  Association of basophil parameters with disease severity and duration in chronic spontaneous urticaria (CSU).

Authors:  Amy H Huang; Kristin L Chichester; Sarbjit S Saini
Journal:  J Allergy Clin Immunol Pract       Date:  2019-08-14

2.  Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria.

Authors:  Eric Tyrell Oliver; Kris Chichester; Kelly Devine; Patricia Meghan Sterba; Craig Wegner; Becky Marie Vonakis; Sarbjit Singh Saini
Journal:  Int Arch Allergy Immunol       Date:  2019-03-15       Impact factor: 2.749

Review 3.  Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.

Authors:  A P Kaplan; A M Giménez-Arnau; S S Saini
Journal:  Allergy       Date:  2017-01-04       Impact factor: 13.146

Review 4.  Urticaria and Angioedema: an Update on Classification and Pathogenesis.

Authors:  Susanne Radonjic-Hoesli; Kathrin Scherer Hofmeier; Sara Micaletto; Peter Schmid-Grendelmeier; Andreas Bircher; Dagmar Simon
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

5.  Chronic Idiopathic Urticaria: Systemic Complaints and Their Relationship with Disease and Immune Measures.

Authors:  Judy C Doong; Kris Chichester; Eric T Oliver; Lawrence B Schwartz; Sarbjit S Saini
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-14

Review 6.  Chronic Spontaneous Urticaria: The Devil's Itch.

Authors:  Sarbjit S Saini; Allen P Kaplan
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jul - Aug

Review 7.  Current and emerging treatments for chronic spontaneous urticaria.

Authors:  Kirti J Johal; Sarbjit S Saini
Journal:  Ann Allergy Asthma Immunol       Date:  2019-09-05       Impact factor: 6.347

8.  Sleep Disturbance in Patients with Urticaria and Atopic Dermatitis: An Underestimated Burden.

Authors:  Caroline Mann; Matthias Dreher; Hans-Günter Weeß; Petra Staubach
Journal:  Acta Derm Venereol       Date:  2020-03-12       Impact factor: 3.875

9.  The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.

Authors:  Kirti J Johal; Kristin L Chichester; Eric T Oliver; Kelly C Devine; Anja P Bieneman; John T Schroeder; Donald W MacGlashan; Sarbjit S Saini
Journal:  J Allergy Clin Immunol       Date:  2021-03-10       Impact factor: 14.290

10.  Suppression of basophil FcɛRI activation by serum from active chronic idiopathic/spontaneous urticaria (CIU/CSU) subjects.

Authors:  Patricia M Sterba; Robert G Hamilton; Sarbjit S Saini
Journal:  J Invest Dermatol       Date:  2015-02-03       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.